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The Children’s Cancer Survivorship Study reports more chronic illnesses in sarcoma survivors than other
pediatric cancers. Chemotherapy and radiation put survivors at risk for developing chronic illnesses, including
heart disease, diabetes, hypertension, and kidney failure. Sarcoma survivors may have a reduced life expectancy
and signs of heart disease in their 30s and 40s. Since these medical problems occur much later in the general
population, they often go undetected or misdiagnosed in sarcoma survivors, creating delays in intervention and
treatment. The good news is that these chronic illnesses can often be prevented or minimized. The most
common adverse effect of chemotherapy and radiation is coronary artery disease (CAD). CAD has a number of
risk factors, including hypertension, diabetes, obesity, and dyslipidemia. These risk factors are modifiable with
lifestyle changes, including diet and exercise, and/or pharmacological intervention. By identifying and man-
aging risk factors like hypertension early, we in turn reduce the risk for CAD and prolong survival. This is well
established in the general population; there is no reason a priori not to apply it to sarcoma survivors. Sarcoma
survivors should be followed by physicians who understand the late effects and outcomes of sarcoma treatment.
The University of Michigan Sarcoma Survivorship Clinic provides long-term care for sarcoma survivors by
preventing, diagnosing, and treating the adverse long-term physical and psychological effects associated with
sarcoma survivorship.
Sarcoma Survivors: A Unique At-Risk Population
Bone and soft tissue sarcomas are rare cancers, but rep-
resent a significant proportion of cancers diagnosed in ado-
lescents and young adults. The majority of patients diagnosed
with sarcoma will be cured of their disease and live cancer
free. Diagnosed as children, adolescents, or adults, sarcoma
survivors are at a great risk of developing a severe or life-
threatening chronic medical condition1,2 related to their sar-
coma treatment as they age. Survivors face issues specific to
their surgeries, radiation treatment, systemic chemotherapy,
and psychosocial issues that can have a major impact on long-
term health.
The Children’s Cancer Survivorship Study3 Report reveals
rates of severe chronic illnesses in sarcoma survivors much
higher than those found in other pediatric cancers. Sarcoma
survivors, despite being cured, may have a reduced life ex-
pectancy and sometimes show signs in their 30s and 40s of
heart disease seen in older adults. Acquired heart disease in a
30-year-old is rare; heart disease in a 30-year-old sarcoma
survivor is not. In fact, heart disease is the main issue facing
sarcoma survivors.4 Doxorubicin is the most common che-
motherapy given to sarcoma patients that causes cardiac
toxicity, much of which is irreversible. The progression to
heart failure may be prevented with early intervention if
screened for early. Other potential conditions include type 2
diabetes, high blood pressure, lipid disorders, kidney failure,
anxiety, depression and other mental health problems, sar-
coma recurrence, and new secondary cancer(s).3 These ill-
nesses can occur as soon as 2 years after completing sarcoma
treatment (Fig. 1).
Since these medical problems occur much later in the
general population, they often go undetected or mis-
diagnosed in sarcoma survivors,5 creating delays in inter-
vention and treatment. The good news is that these chronic
illnesses can often be prevented or minimized. The most
common adverse effect of chemotherapy and radiation is
coronary artery disease (CAD). CAD has a number of risk
factors, including hypertension, diabetes, obesity, and dys-
lipidemia. These risk factors are modifiable with lifestyle
changes, including diet and exercise, and/or pharmacolog-
ical intervention. By identifying and managing risk factors
like hypertension early, we in turn reduce the risk for CAD
and prolong survival. This is well established in the general
population; there is no reason a priori not to apply it to
sarcoma survivors (Fig. 2).
The Institute of Medicine and the American Society of
Clinical Oncology (ASCO)’s shared care model6 for breast
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cancer, prostate cancer, and colon cancer survivors between
the medical oncologist and the primary care physician are
unlikely to meet the needs of a sarcoma survivor. In January
2014, the Annals of Internal Medicine7 reported that on av-
erage, internists were ‘‘somewhat uncomfortable’’ caring for
survivors of Hodgkin lymphoma, acute lymphoblastic leuke-
mia, and osteosarcoma. Sarcoma survivors are best followed
by physicians familiar with the chronic effects of sarcoma
treatment especially systemic therapies as well as the local/
regional therapies of surgery and radiation therapy.
The University of Michigan Sarcoma Survivorship Clinic
Medical oncologist, Laurence H. Baker, DO has been
treating sarcoma patients for more than 40 years and believes
that sarcoma survivors should be appropriately followed by
FIG. 1. Cumulative incidence of severe, disabling, life-threatening, or fatal chronic health conditions among 2124
sarcoma survivors diagnosed in 1970–1986.3,8
FIG. 2. Cardiovascular risk factors and major cardiac events.4
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physicians who understand the late effects and outcomes of
cancer treatment for sarcoma as well as the potential compli-
cations to look for in the future. In October 2014, he created the
University of Michigan Sarcoma Survivorship Clinic.
The Clinic offers proactive lifelong care, including system-
atic planning for cancer prevention and patient-centered sur-
veillance based on the survivor’s personal risk, cancer therapy,
genetic predispositions, lifestyle behaviors, and other comorbid
health conditions. Regardless of where a patient was treated or
lives in the country, the clinic is open to sarcoma survivors 16
years and older who have been off therapy for at least 2 years
and to patients who are transitioning from pediatric to adult
medical care. Survivor patients may self-refer or physicians may
refer patients to the Sarcoma Survivorship Clinic.
Sarcoma survivors are unique individuals whose needs
range from those with few long-term effects from their
treatment to patients with chronic conditions or significant
treatment-related health issues. Providing survivorship care
requires a variety of approaches to meet their needs. All
survivors require education regarding their individual health
risks and screening needs. The Sarcoma Survivorship Clinic
focuses on the survivor’s total well-being, creating strategies
to best manage any healthcare issues that may arise.
We provide a comprehensive health exam and deter-
mine a patient’s risk of developing chronic illnesses based
on their treatment and medical history. There is a strong
focus on cardiovascular chronic illness. Signs of con-
gestive heart failure are observed and screened with
echocardiography. Patients who received Doxorubicin are
screened annually for cardiomyopathy with an echocar-
diogram with strain. Preventive measures are available for
those patients who received radiation to the chest. This
includes cholesterol lowering and assessing obesity with
functional status. We apply well-established criteria for
cancer screening prospectively. Survivors are followed for
skeletal-muscular dysfunction, metabolic syndrome, dia-
betes, hypertension, cardiac diseases, anxiety, depression,
renal insufficiency (for more careful inspection of drug
toxicity), and obesity. Visits typically include laboratory
blood and urine tests, a 6-minute hall walk (to assess
physical function), as well as a meeting with a dietician to
assist with weight management.
Patients complete risk assessment questions for us to learn
their perception of risk of their sarcoma returning, the possi-
bility of a secondary cancer, and the possibility of developing
chronic health condition(s) related to their sarcoma treatment.
This assessment informs us how best to tailor the educational
component of the appointment to teach the patient about their
individual risks based on their prior treatment and medical and
family history. Patients are also evaluated with questions from
the National Institutes of Health’s (NIH) Patient-Reported
Outcome Measurement Information System (PROMIS), a
Table 1. Data for the First 30-Patient Cohort
Patient reported Sarcoma survivorship clinic
Patients (n) Patients (n)
Received a survivorship plan when
completed sarcoma treatment
13% (4) Age at diagnosis
Range (8–61)
Before age 30 53% (16)
Family history
of cancer
First degree relative 30% (9) Mean 32 years
More than one
23% (7)
Median 35 years
first degree relative
Second degree
relative
63% (19) Mode 19 years 17% (5)
Patient-reported
diagnosis or
treatment for
Second cancer
(in addition to
sarcoma)
20% (6) New findings Hypertension
Cardiomyopathy
33% (10)
Hypertension 17% (5)
7% (2)
Cardiac issues
(congestive heart
failure and coronary
artery disease)
10% (3)
At risk of developing
cardiac disease
secondary to
chemotherapy
20% (6)
Anxiety 30% (9)
Diabetes 3% (1)
Depression 23% (7)
Hyperlipidemia 20% (6)
Osteopenia/
osteoporosis
20% (6)
Renal insufficiency
Thyroid dysfunction
10% (3)
10% (3)
Renal function issues/
kidney disease
3% (1)
Osteoporosis
Osteoarthritis
10% (3)
3% (1)
Concerns about
fertility
23% (7)
Thoracic aneurism
Sinus tachycardia
3% (1)
3% (1)
Concerns about sleep
quality
17% (5)
Hearing loss 7% (2)
Fear 27% (8)
Depression 13% (4)
Recommendations Recommended
regular cancer
screening
20% (6)
Recommended
weight loss
50% (15)
Recommended
exercise
50% (15)
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system of highly reliable, precise measures of patient-reported
health status. Our patients complete the PROMIS question-
naires on Anxiety, Depression, Mobility, Pain Interference,
Sleep Disturbance, and Physical Function before their first
clinic visit and then every 6 months thereafter. If the patient
already has an early diagnosis of a chronic medical disease, we
will consult and work closely with the appropriate specialist to
formulate the best treatment plan. Based on the clinic visit, we
may refer patients to a specialist on our team, which includes
onco-cardiology, nephrology, pulmonary medicine, orthope-
dic surgery, radiation oncology, psychiatry, physical medicine
and rehabilitation (PM&R), endocrinology, gynecology, and
internal medicine. In addition to our individualized educational
component, patients receive a Sarcoma Survivorship Care
Plan to empower them with the knowledge of their treat-
ment history, personalized risk assessment, monitoring rec-
ommendations, referrals to specialists, and recommendations
for health-protective behaviors. For continuity of care, these
plans are also shared with the patient’s physicians. The pa-
tient’s survivorship plan reflects the regular patient assess-
ments to address the survivor’s changing needs over time.
Unless presenting chronic or severe life-threatening issues,
patients are seen annually and undergo a series of examinations
to monitor for chronic illnesses and measure performance such
as physical strength and cognitive function. The Program’s
regular clinic visits and the patient questionnaires will allow us to
monitor and recognize potential physical and mental conditions
over time. This regular contact will also allow us to diagnose and
treat any conditions earlier, and with better outcomes.
The Long-Term Impact of Sarcoma Treatment
Our Sarcoma Survivorship Program database captures data
on specific cancer(s), treatment regimen(s), chronic illness
history, family health history, laboratory data, as well as the
prospective data: the long-term and late physical and psycho-
logical effects of cancer and its treatment and any comorbid
medical conditions. The Sarcoma Survivorship Program da-
tabase was created to teach us about the potential of early
recognition and intervention, and confirm that earlier identifi-
cation improves long-term function, reduces debilitating
symptoms, and potentially reduces mortality (Table 1). With-
out appropriate awareness of late effects by patients and/or
providers, symptoms may be discounted and/or attributed to
other causes, leading to misinformed evaluation and possibly
delayed and/or inappropriate treatment. It is critical that we
improve our knowledge of the long-term impact of cancer
therapy to effectively counsel survivors and offer effective
intervention strategies to prevent or minimize the impact of
adverse late effects.
Since opening the Survivorship Clinic in October 2014, our
patients have confirmed they are deficient in health-related
knowledge and are not engaged in consensus health promotion
and screening practices that could improve their long-term
outcomes. In fact, when asked questions such as ‘‘to what
degree of certainty do you think you are cured of your sarco-
ma?’’ and ‘‘because of your sarcoma treatment, to what extent
do you think that you are at risk of developing significant heart
disease, hypertension, kidney failure, anxiety, depression and
other mental health problems, the sarcoma returning, or de-
veloping a new cancer?,’’ only 40% were knowledgeable
about some of the adverse effects. This may be because only
13% received a Survivorship Plan when they completed their
treatment or the failure of the treating oncologist to discuss
their risks.3 Our research addresses the specific gaps in
knowledge such as the incidence of and risk factors for late and
long-term effects of sarcoma and its treatment. Now that we
have started seeing our patients again for their annual visit, we
will be able to monitor adverse effects over time.
The purpose of the Sarcoma Survivorship Program is to
provide patients with strategies to optimize their overall health
and wellness, now and in the future. The program aims to provide
excellent clinical care to patients while fostering clinical re-
search that will lead to further advances in care for sarcoma
survivors to prevent morbidity/lethality of chronic medical
conditions and to improve the quality of life in sarcoma survivors
of all ages. We are pursuing research to develop more effective
strategies that can be developed to precisely identify sarcoma
survivors at greatest risk for specific outcomes.
University of Michigan Sarcoma Survivorship Program:
www.mcancer.org/sarcoma-survivorship
University of Michigan Sarcoma Survivorship Clinic: www
.mcancer.org/sarcoma-survivorship/sarcoma-survivorship-clinic
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